35981 |
Oncology |
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary p... |
EUR J CANCER 2020 10.1016/j.ejca.2020.03.029 |
안진석 |
2020 |
35980 |
Oncology |
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation... |
J CLIN ONCOL 2020 10.1200/JCO.19.00457 |
안진석 |
2020 |
35979 |
Oncology |
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Unc... |
J CLIN ONCOL 2020 10.1200/JCO.19.00931 |
안진석 |
2020 |
35978 |
Ophthalmology |
Markedly increased ocular side effect causing severe vision deteriorat... |
BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9 |
안진석 |
2020 |
35977 |
Oncology; Immunology |
Immune-related adverse events are clustered into distinct subtypes by ... |
Oncoimmunology 2020 10.1080/2162402X.2020.1722023 |
안진석 |
2020 |
35976 |
Oncology |
Genomic landscape of acquired resistance to third-generation EGFR tyro... |
CANCER 2020 10.1002/cncr.32809 |
안진석 |
2020 |
35975 |
Oncology; Pharmacology & Pharmacy |
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lu... |
INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3 |
안진석 |
2020 |
35974 |
Oncology |
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pa... |
CANCERS 2020 10.3390/cancers12051306 |
안진석 |
2020 |
35973 |
Medicine, Research & Experimental |
Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Pa... |
IN VIVO 2020 10.21873/invivo.11920 |
안진석 |
2020 |
35972 |
Oncology |
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Pa... |
CANCER RES TREAT 2020 10.4143/crt.2019.186 |
안진석 |
2020 |